CA2382030A1 - Compositions et procedes d'inhibition de l'infection au virus de l'immunodeficience humaine, par regulation restrictive de genes cellulaires humains - Google Patents

Compositions et procedes d'inhibition de l'infection au virus de l'immunodeficience humaine, par regulation restrictive de genes cellulaires humains Download PDF

Info

Publication number
CA2382030A1
CA2382030A1 CA002382030A CA2382030A CA2382030A1 CA 2382030 A1 CA2382030 A1 CA 2382030A1 CA 002382030 A CA002382030 A CA 002382030A CA 2382030 A CA2382030 A CA 2382030A CA 2382030 A1 CA2382030 A1 CA 2382030A1
Authority
CA
Canada
Prior art keywords
seq
protein
nucleic acid
cell
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002382030A
Other languages
English (en)
Inventor
Tanya A. Holzmayer
Stephen J. Dunn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Target Discovery Inc
PPD Development LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Target Discovery Inc, PPD Development LP filed Critical Target Discovery Inc
Publication of CA2382030A1 publication Critical patent/CA2382030A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des molécules d'acides nucléiques impliquées dans l'infection au HIV, des protéines codées par de telles molécules, ainsi que des composés protecteurs comprenant ces molécules d'acides nucléiques, ces protéines, et des inhibiteurs de produits codés par lesdites molécules. En outre, l'invention concerne également des procédés d'identification d'éléments suppresseurs génétiques supplémentaires, des gènes cellulaires correspondant à de tels éléments suppresseurs génétiques, ainsi que des procédés d'utilisation de ces gènes cellulaires et des produits de ceux-ci, codés, dans des méthodes de criblage destinées à la sélection d'inhibiteurs supplémentaires du HIV.
CA002382030A 1999-09-01 2000-09-01 Compositions et procedes d'inhibition de l'infection au virus de l'immunodeficience humaine, par regulation restrictive de genes cellulaires humains Abandoned CA2382030A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38818299A 1999-09-01 1999-09-01
US09/388,182 1999-09-01
PCT/US2000/024262 WO2001016322A2 (fr) 1999-09-01 2000-09-01 Compositions et procedes d'inhibition de l'infection au virus de l'immunodeficience humaine, par regulation restrictive de genes cellulaires humains

Publications (1)

Publication Number Publication Date
CA2382030A1 true CA2382030A1 (fr) 2001-03-08

Family

ID=23533027

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002382030A Abandoned CA2382030A1 (fr) 1999-09-01 2000-09-01 Compositions et procedes d'inhibition de l'infection au virus de l'immunodeficience humaine, par regulation restrictive de genes cellulaires humains

Country Status (6)

Country Link
EP (1) EP1238072A2 (fr)
JP (1) JP2003510033A (fr)
AU (1) AU771546B2 (fr)
CA (1) CA2382030A1 (fr)
IL (1) IL148225A0 (fr)
WO (1) WO2001016322A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030087273A1 (en) * 2001-06-29 2003-05-08 Holzmayer Tanya A. Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
CU23896B1 (es) * 2010-04-01 2013-05-31 Ct De Ingeniería Genética Y Biotecnología Método para inhibir la replicación del vih en células de mamíferos
BR112016016130A2 (pt) 2014-01-10 2017-08-08 Glaxosmithkline Ip No 2 Ltd Compostos e métodos
AU2015204452A1 (en) 2014-01-13 2016-08-11 Berg Llc Enolase 1 (Eno1) compositions and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL83003A (en) * 1986-07-01 1995-07-31 Genetics Inst Osteoinductive factors
US6071743A (en) * 1997-06-02 2000-06-06 Subsidiary No. 3, Inc. Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes

Also Published As

Publication number Publication date
AU7346600A (en) 2001-03-26
IL148225A0 (en) 2002-09-12
AU771546B2 (en) 2004-03-25
WO2001016322A3 (fr) 2002-07-11
WO2001016322A2 (fr) 2001-03-08
EP1238072A2 (fr) 2002-09-11
JP2003510033A (ja) 2003-03-18

Similar Documents

Publication Publication Date Title
Mizuki et al. Functional modules and expression of mouse p40 phox and p67phox, SH3‐domain‐containing proteins involved in the phagocyte NADPH oxidase complex
US20050019304A1 (en) Novel human mage-like protein
US6326152B1 (en) Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
CA2496891A1 (fr) Nouveau lacs de proteine cytosquelette associee a actine
US20050142538A1 (en) Viral receptor protein
AU771546B2 (en) Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
US6537972B1 (en) Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
US6613506B1 (en) Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
JPWO2000029571A1 (ja) 新規膜貫通蛋白質をコードする遺伝子
US20030044401A1 (en) Novel glutathione s-transferase
JP2001511645A (ja) ヒトＣ５ａ様受容体
WO2001016323A2 (fr) Compositions et procedes d'inhibition de l'infection due au virus de l'immunodeficience humaine a l'aide de genes cellulaires humains a regulation negative
US7517957B2 (en) Human SLAP-2: a novel SH2/ SH3 domain-containing human SLAP homologue having immune cell-specific expression
US5840534A (en) Human SMT3-like protein
US5756332A (en) Guanosine monophosphate reductase
WO2004061088A2 (fr) Compositions et methodes d'inhibition d'une infection par le virus de l'immunodeficience humaine par regulation vers l'aval de genes cellulaires humains
US7101686B1 (en) Polynucleotides encoding human SLAP-2:a novel SH2/SH3 domain-containing human SLAP homologue having immune cell-specific expression
US7018822B1 (en) Guanosine monophosphate reductase
WO2004053094A2 (fr) Compositions et procedes permettant d'inhiber l'infection par le virus de l'immunodeficience acquise par freination des genes cellulaires humains
US20030215916A1 (en) Novel imidazoline receptor homologs
JP2004532619A (ja) 細胞内シグナル伝達カスケードに関与する新規なヒト遺伝子ｒｅｔ１６の同定およびクローニング
US20040072773A1 (en) Novel functions for dp214
US20020038006A1 (en) Human extracellular matrix proteins

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued